Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States: a real-world analysis. Blood Adv 2024 Feb 13;8(3):549-552
Date
12/13/2023Pubmed ID
38091577Pubmed Central ID
PMC10835265DOI
10.1182/bloodadvances.2023011698Scopus ID
2-s2.0-85185395343 (requires institutional sign-in at Scopus site)Author List
Epperla N, Zhao Q, Moyo T, Watkins MP, Tavakkoli M, Bello C, Torka P, Reddy N, Thomas C, Annunzio K, Christian B, Barta SK, Shouse G, Olszewski AJ, Bartlett NLAuthor
Kaitlin Annunzio DO Assistant Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdenineHumans
Lymphoma, B-Cell, Marginal Zone
Piperidines
United States
